Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25544303 | 0.85 | DNM1 (0.42) | DNM1ALDH1A1TSHR | |
| SCHEMBL25544301 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL25544299 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL26373556 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL25544307 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL25544298 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL25544310 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL25544306 | 0.83 | DNM1 (0.45) | DNM1TSHR | |
| SCHEMBL7644959 | 0.78 | ALDH1A1 (0.42) | CYP3A4DNM1ALDH1A1TDP1LMNA | |
| SCHEMBL18338907 | 0.76 | DNM1 (0.42) | DNM1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029795-B2 | Base editing of PCSK9 and methods of using same for treatment of disease | VERVE THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | PCSK9, LDLR, PCSK7 | CYP3A4 4650/4885DNM1 862/4885ALDH1A1 2571/4885 |
| US-12029795-B2 | Base editing of PCSK9 and methods of using same for treatment of disease | PCSK9, LDLR, PCSK7 | CYP3A4 4650/4885DNM1 862/4885ALDH1A1 2571/4885 |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | LDLR, LIPC, SREBF2 | CYP3A4 3126/4885DNM1 1519/4885ALDH1A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.